ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

UHS vs MRK // REVENUE GROWTH (YOY)

Universal Health Services Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: UHS 6 — MRK 9
▲ REVENUE GROWTH (YOY) LEADER: UHS
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UHS VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC UHS MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 41.00% 74.80% -33.80 MRK /gross-margins <GO>
Return on Invested Capital (ROIC) 14.10% 20.70% -6.60 MRK /roic <GO>
EV/EBITDA & P/E Valuation 5.0x 15.3x -10.30 UHS /valuation <GO>
Free Cash Flow Yield 8.16% 3.42% +4.74 UHS /fcf-yield <GO>
Operating Margin 11.50% 34.30% -22.80 MRK /operating-margins <GO>
Net Profit Margin 8.60% 28.10% -19.50 MRK /net-margins <GO>
Revenue Growth (YoY) ACTIVE 9.70% 1.30% +8.40 UHS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.49% 2.26% -1.77 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.11 5.19 -2.08 MRK /balance-sheet <GO>
Piotroski F-Score Quality 9/9 7/9 +2.00 UHS /piotroski-score <GO>
Options Implied Move & Put/Call Skew 7.00% 6.60% +0.40 MRK /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.7 56.9 -11.20 MRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.04 0.92 +0.12 UHS /macro-sensitivity <GO>
Forward P/E Multiple 6.5x 18.4x -11.90 UHS /forward-pe <GO>
Enterprise Scale & Market Cap $10.41B $361.02B -$350.61B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR UHS REV MRK REV UHS GROSS % MRK GROSS % UHS FCF MRK FCF
FY 2025 $17.36B $65.01B 44.0% 74.8% $849.2M $12.36B
FY 2024 $15.83B $64.17B 44.0% 76.3% $1.12B $18.10B
FY 2023 $14.28B $60.12B 44.0% 44.0% $625.1M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UHS // BETA 1.04
MRK // BETA 0.92